



## Fabio Girardi

**Nationality:** Italian **Date of birth:** 22/10/1980 **Gender:** Male

**Phone number:** (+39) 0498215931 **Email address:** [fabio.girardi@iov.veneto.it](mailto:fabio.girardi@iov.veneto.it)

### WORK EXPERIENCE

---

#### Consultant Medical Oncologist

*Istituto Oncologico Veneto IRCCS* [ 01/09/2020 – Current ]

City: Padova

Country: Italy

#### Honorary (Clinical) Assistant Professor in Cancer Epidemiology

*London School of Hygiene and Tropical Medicine* [ 14/12/2021 – Current ]

City: London

Country: United Kingdom

#### Full registration with a licence to practise and entry on the Specialist Register

*General Medical Council* [ 20/04/2016 – Current ]

City: London

Country: United Kingdom

#### Honorary Consultant Oncologist

*University College London Hospitals NHS Foundation Trust* [ 08/08/2018 – 01/05/2021 ]

City: London

Country: United Kingdom

#### Consultant Medical Oncologist

*Azienda ULSS 2 Marca Trevigiana – Regione Veneto* [ 01/03/2020 – 31/08/2020 ]

City: Treviso

Country: Italy

#### ESMO Examination

*European Society for Medical Oncology* [ 28/09/2019 ]

#### Consultant Medical Oncologist

*Azienda ULSS 2 Marca Trevigiana – Regione Veneto* [ 01/02/2013 – 30/08/2017 ]

City: Castelfranco Veneto

Country: Italy

#### Consultant Medical Oncologist

*Azienda USL Bologna - Regione Emilia Romagna* [ 01/03/2012 – 31/01/2013 ]

City: Bologna

Country: Italy

#### Consultant Medical Oncologist

*Azienda ULSS 2 Marca Trevigiana – Regione Veneto* [ 03/05/2010 – 29/02/2012 ]

City: Castelfranco Veneto

Country: Italy

### **National Medical Licence**

*Università degli Studi di Padova* [ 15/02/2006 ]

City: Padova

Country: Italy

## **EDUCATION AND TRAINING**

---

### **PhD in Epidemiology and Population Health**

*London School of Hygiene and Tropical Medicine (United Kingdom)* [ 25/09/2017 – 25/04/2021 ]

Thesis: "Global surveillance of survival from intrinsic brain tumours diagnosed during 2000-2014: trends by age and histology". Supervisors: Professor Claudia Allemani, Professor Michel Coleman

### **Master of Philosophy in Epidemiology**

*University of Cambridge (United Kingdom)* [ 06/10/2015 – 29/07/2016 ]

Thesis: "Using data from the EMBRACE prospective cohort of families with BRCA1/BRCA2 mutations to estimate cancer risks for family members who do not carry the family mutations". Supervisor: Professor Antonis Antoniou

### **Specialty training, Medical Oncology**

*Università degli Studi di Padova (Italy)* [ 2006 – 2009 ]

### **Medical Degree**

*Università degli Studi di Padova (Italy)* [ 1999 – 2005 ]

## **LANGUAGE SKILLS**

---

Mother tongue(s): **Italian**

Other language(s):

#### **English**

LISTENING C2 READING C2 WRITING C1

SPOKEN PRODUCTION C1 SPOKEN INTERACTION C1

#### **German**

LISTENING B1 READING B1 WRITING B1

SPOKEN PRODUCTION B1 SPOKEN INTERACTION B1

## **DIGITAL SKILLS**

---

Office™ (Word™, Excel™, Power Point™) / STATA (advanced) / Reference Management softwares Zotero EndNote Mendeley

## **PUBLICATIONS**

---

### **Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000-2014 (CONCORD-3)**

Neuro-Oncology, 2022

[Girardi E](#), Matz M, Stiller C, You H, Marcos Gragera R, Valkov MY, Bulliard J, De P, Morrison D, Wanner M, O'Brian DK, Saint-Jacques N, Coleman MP, Allemani C, CONCORD Working Group

### **Global survival trends for brain tumours, by histology: analysis of individual records for 67,776 children diagnosed in 61 countries during 2000-2014 (CONCORD-3)**

Neuro-Oncology, 2022

[Girardi E](#), Di Carlo V, Stiller C, Gatta G, Woods RR, Visser O, Lacour B, Tucker TC, Coleman MP, Allemani C, CONCORD Working Group

## **Reply to "Reporting pediatric brain tumors according to their behavior code can result in biased survival estimates-A European perspective to Girardi et al"**

Neuro-Oncology, 2022; epub ahead of print

[Girardi E](#), Coleman MP, Allemani C

## **Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000–14 (CONCORD-3): analysis of individual data from 258 cancer registries in 61 countries**

The Lancet Child & Adolescents Health, 2022; epub ahead of print

Ssenyonga N, Stiller C, Nakata K, Shalkow J, Redmond S, Bulliard J, [Girardi E](#), Fowler C, Marcos-Gragera R, Bonaventure A, Saint-Jacques N, Minicozzi P, De P, Rodríguez-Barranco M, Larønningen S, Di Carlo V, Mägi M, Valkov M, Seppä K, Wyn Huws D, Coleman MP, Allemani C, CONCORD Working Group

## **Does the morphology of cutaneous melanoma help explain the international differences in survival? Results from 1,578,482 adults diagnosed during 2000-2014 in 59 countries (CONCORD-3)**

British Journal of Dermatology, 2022; epub ahead of print

Di Carlo V, Stiller CA, Eisemann N, Bordoni A, Matz M, Curado MP, Daubisse-Marliac L, Valkov M, Bulliard J, Morrison D, Johnson C, [Girardi E](#), Marcos-Gragera R, Šekerija M, Larønningen S, Sirri E, Coleman MP, Allemani C, CONCORD Working Group

## **Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials**

ESMO Open, 2022; 7:100433

Guarneri V, Griguolo G, Miglietta F, Conte PF, Dieci MV, [Girardi E](#)

## **Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: survival analyses of the CHER-Lob trial**

European Journal of Cancer, 2021;153:133-141

Guarneri V, Dieci MV, Griguolo G, Miglietta F, [Girardi E](#), Bisagni G, Generali DG, Cagossi K, Sarti S, Frassoldati A, Gianni L, Cavanna L, Pinotti G, Musolino A, Piacentini F, Cinieri S, Prat A, Conte PF, CHER-Lob Study Team

## **The histology of brain tumours for 67,331 children and 671,085 adults diagnosed in 60 countries during 2000-2014: a global, population-based study (CONCORD-3)**

Neuro-Oncology, 2021; 23:1765-1776

[Girardi E](#), Rous B, Stiller CA, Gatta G, Fersht N, Storm HH, Rodrigues JR, Herrmann C, Marcos-Gragera R, Peris-Bonet R, Valkov M, Weir HK, Woods RR, You H, Cueva PA, De P, Di Carlo V, Johannesen TB, Lima CA, Lynch CF, Coleman MP, Allemani C, CONCORD Working Group

## **Trends in short-term survival from distant-stage cutaneous melanoma in the United States, 2001-2013 (CONCORD-3)**

JNCI Cancer Spectrum, 2020; 4:pkaa078

Di Carlo V, Estève J, Johnson C, [Girardi E](#), Weir HK, Wilson RJ, Minicozzi P, Cress RD, Lynch CF, Pawlish KS, Rees JR, Coleman MP, Allemani C; US CONCORD Working Group

## **Global trends in survival from astrocytic tumours in adolescents and young adults: a systematic review**

JNCI Cancer Spectrum, 2020; 4:pkaa049

[Girardi E](#), Allemani C, Coleman MP

## **Sustainable care for children with cancer: a Lancet Oncology Commission**

Lancet Oncology, 2020; 21:e185-224

Atun R, Bhakta N, Denburg A, Frazier AL, Friedrich P, Gupta S, Lam CG, Ward ZJ, Yeh JM, Allemani C, Coleman MP, Di Carlo V, Loucaides E, Fitchett E, [Girardi E](#), Horton SE, Bray F, Steliarova-Foucher E, Sullivan R, Aitken JF, Banavali

S, Binagwaho A, Alcasabas P, Antillon F, Arora RS, Barr RD, Bouffet E, Challinor J, Fuentes-Alabi S, Gross T, Hagander L, Hoffman RI, Herrera C, Kutluk T, Marcus KJ, Moreira C, Pritchard-Jones K, Ramirez O, Renner L, Robison LL, Shalkow J, Sung L, Yeoh A, Rodriguez-Galindo C

### **Colorectal cancer incidence among young adults in England: trends by anatomical sub-site and deprivation**

PLoS One, 2019; 14:e0225547

Exarchakou A, Donaldson LJ, [Girardi E](#), Coleman MP

### **World-wide trends in survival from common childhood brain tumours: a systematic review**

JCO Global Oncology, 2019; 5:1-25

[Girardi E](#), Allemani C, Coleman MP

### **Global childhood cancer survival estimates and priority-setting: a simulation-based analysis**

Lancet Oncology, 2019; 20:972-983

Ward ZJ, Yeh JM, Bhakta N, Frazier AL, [Girardi E](#), Atun R

### **Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study**

Genetics in Medicine, 2018; 20:1575-1582

[Girardi E](#), Barnes DR, Barrowdale D, Frost D, Brady AF, Miller C, Henderson A, Donaldson A, Murray A, Brewer C, Pottinger C, Evans DG, Eccles D; EMBRACE, Laloo F, Gregory H, Cook J, Eason J, Adlard J, Barwell J, Ong KR, Walker L, Izatt L, Side LE, Kennedy MJ, Tischkowitz M, Rogers MT, Porteous ME, Morrison PJ, Eeles R, Davidson R, Snape K, Easton DF, Antoniou AC

### **Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies**

Oncologist, 2010; 15:683-694

[Girardi E](#), Franceschi E, Brandes AA

### **Bevacizumab in brain tumors: ready for primetime**

Future Oncology, 2009; 5:1183-1184

Franceschi E, Tosoni A, [Girardi E](#), Brandes AA

## **CONFERENCES AND SEMINARS**

---

### **NAACCR /IACR Combined Annual Conference**

[ Vancouver (Canada), 13/06/2019 ]

Oral presenter. Concurrent Session 5B, Survival and Brain and CNS

### **ESMO Congress**

[ Barcelona (Spain), 28/09/2019 ]

Poster presenter. Central Nervous System Tumours Poster Session, abstract 410P

### **NAACCR /IACR Combined Annual Conference**

[ Vancouver (Canada), 11/06/2019 ]

Poster presenter. Poster Session, abstract PS-5

### **ESMO Congress**

[ Munich (Germany), 22/10/2018 ]

Poster presenter. Public Health Policy Poster Session, abstract 1597P

## **ESMO Congress**

[ Munich (Germany), 22/10/2018 ]

Poster presenter. Central Nervous System Tumours Poster Session, abstract 383P

## **ASCO Annual Meeting**

[ Chicago (United States), 05/06/2017 ]

Poster presenter. Cancer Prevention, Genetics and Epidemiology Poster Session, abstract 1558

## **HONOURS AND AWARDS**

---

### **Merit Award**

European Society for Medical Oncology [ 29/09/2019 ]

Travel grant

### **Merit Award**

European Society for Medical Oncology [ 22/10/2018 ]

Travel grant

### **Jane Davidson & Paul O'Gorman Doctoral Fellowship**

London School of Hygiene and tropical Medicine [ 20/03/2017 ]

Doctoral scholarship

### **Medical Research Council Master of Philosophy Studentship**

University of Cambridge [ 23/07/2015 ]

MPhil Studentship

## **SHORT COURSES**

---

### **Global Health Short Course. Imperial College School of Public Health. London (United Kingdom)**

[ 23/06/2014 – 27/06/2014 ]

## **SCIENTIFIC SOCIETIES**

---

### **European Society for Medical Oncology (ESMO)**

[ 2018 – Current ]

## **GRANT APPLICATION PEER REVIEW**

---

### **Integrated Research Action Programme (PAIR)**

[ 25/03/2021 – 29/09/2021 ]

Institut National du Cancer (INCa), France